These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15976506)

  • 1. Selective COX-2 inhibitors and risk of myocardial infarction.
    Krotz F; Schiele TM; Klauss V; Sohn HY
    J Vasc Res; 2005; 42(4):312-24. PubMed ID: 15976506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent development of selective cyclooxygenase-2 inhibitors].
    Kawai S
    Nihon Rinsho; 2002 Dec; 60(12):2370-7. PubMed ID: 12510364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers].
    Ohara M; Sawa T
    Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
    Martínez-González J; Badimon L
    Curr Pharm Des; 2007; 13(22):2215-27. PubMed ID: 17691994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events.
    Mitchell JA; Lucas R; Vojnovic I; Hasan K; Pepper JR; Warner TD
    FASEB J; 2006 Dec; 20(14):2468-75. PubMed ID: 17142796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
    Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
    J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
    Burdan F; Korobowicz A
    Pol Merkur Lekarski; 2003 Apr; 14(82):352-5. PubMed ID: 12868201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Komers R; Anderson S; Epstein M
    Am J Kidney Dis; 2001 Dec; 38(6):1145-57. PubMed ID: 11728945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.